首页 | 本学科首页   官方微博 | 高级检索  
检索        


Bone and primary hyperparathyroidism
Institution:1. Department of Rheumatology, St James’ Hospital, James’ Street, Dublin 8, Ireland;2. School of Medicine, Trinity College, Dublin, Ireland;3. Department of Rheumatology, St Vincent''s Hospital, Dublin, Ireland;1. Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, 563000 Zunyi, China;2. Department of Endocrinology, Affiliated Hospital of Zunyi Medical University, 563000 Zunyi, China;1. Center for Musculoskeletal Surgery, Charité–University Medicine Berlin, Berlin, Germany;2. Department of Orthopaedics and Orthopaedic Surgery, University Medicine Greifswald, Greifswald, Germany;3. Institute of Pathology, Ludwig Maximilian University of Munich, Munich, Germany;1. Department of rheumatology, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France;2. EA 4266, EPILAB, université de Franche-Comté, Besançon, France;3. EpiDermE, université Paris Est Créteil, 94010 Créteil, France;4. Service de rhumatologie, hôpital Henri-Mondor, AP–HP, 94010 Créteil, France;5. Department of rheumatology, CHRU de Tours, Tours, France;6. EA 7501, GICC, université de Tours, Tours, France;7. Department of rheumatology, Aix Marseille université, CHU Sainte-Marguerite, AP–HM, Marseille, France;8. EA 4267, PEPITE, université de Franche-Comté, FHU INCREASE, Besançon, France;1. Internal Medicine Unit, Azienda Sanitaria Locale AL Ospedale Santo Spirito, Casale Monferrato Alessandria, Italy;2. Department of Health Sciences, University of Genova, Genova, Italy;3. Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Specialties (DIMI), University of Genova, IRCCS Rheumatology Unit, San Martino Polyclinic, Viale Benedetto XV, No. 6, 16132 Genova, Italy;4. Department of Internal Medicine, Ghent University, Department of Rheumatology, University Hospital, Ghent, Belgium;5. Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium
Abstract:Primary hyperparathyroidism (PHPT) is a disease caused by excessive and inappropriate secretion of parathyroid hormone resulting in hypercalcemia. It is usually diagnosed incidentally in case of hypercalcemia, osteoporosis or, more rarely, renal involvement such as lithiasis. The clinical presentation reflects hypercalcemia and involves several organs, mainly the cardiovascular system, bone, and kidneys. However, most patients with PHPT are asymptomatic. The diagnosis is biological, obvious when serum calcium and parathyroid hormone levels are high, but difficult when one of these two values is normal. The diagnosis of normocalcemic PHPT is possible only after ruling out all causes of secondary hyperparathyroidism. Parathyroid imaging does not contribute to the positive diagnosis but guides surgery and rules out an associated thyroid abnormality. Parathyroid surgery is the gold standard treatment. Parathyroid surgery is indicated in the presence or risk of complications, and it is the only treatment that prevents fractures. Pharmaceutical treatments have only limited effects on complications and are limited to cases where surgery is contraindicated. After parathyroid surgery, the use of bisphosphonates must be avoided as they seem to interfere with the parathyroidectomy's fracture-preventing effects. In the absence of surgical indication, medical monitoring of patients includes assessment of laboratory values, bone density, and renal function.
Keywords:Primary hyperparathyroidism  Hypercalcemia  Osteoporosis  Nephrolithiasis  Vitamin D
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号